Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nicholas Theodosakis, M.D.


This page shows the publications co-authored by Nicholas Theodosakis and Vartan Pahalyants.
Connection Strength

  1. Reply to: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated. J Am Acad Dermatol. 2022 Mar 29.
    View in: PubMed
    Score: 0.249
  2. Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. Immunol Lett. 2021 Dec 30; 244:43-44.
    View in: PubMed
    Score: 0.245
  3. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022 01; 86(1):252-255.
    View in: PubMed
    Score: 0.239
  4. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.